Hi ss, the ORR is CR + PR so 2/12 = 17%.
Disease Control Rate is sometimes used to describe the sum of the positive outcomes, CR+PR+SD, but is not often used as a primary measure as there is debate around what it accurately represents.
However, in this trial the fact that 9/12=75% of patients achieved at least SD is imho phenomenal. Mono-therapy trial in late stage nsclc where patients had (disease) progressed on all previous SoC PD1/L1 inhibitor treatments. And then they get PD1-vaxx as a mono-therapy and start responding across all dosages.
Simply amazing.
And very good safety profile so far, so why not add it to your block buster drug protocol?
Ann: IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT, page-72
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |